Search

everythinglearnresearchcommunity

for

Search:↓

LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

Platycladi Cacumen may help treat hair loss by affecting certain biological pathways.

Promising cancer treatments were found, but the manufacturer closed.

Cyproterone acetate is effective for treating hirsutism and acne in women by blocking androgens in the skin and also works as a contraceptive.

LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.

Platycladi Cacumen may help treat hair loss by targeting specific proteins and pathways.

A new topical treatment for hair loss shows strong hair growth effects with low toxicity.

Exemestane may protect bones by stimulating osteoblast growth through androgen-related pathways.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

Cyproterone acetate effectively treats sexual disorders by reducing sexual functions and is generally well-tolerated.

Ciproterone acetate improves hair regrowth and acne in most female patients.

The study found that prescribing patterns for Cyproterone Acetate/Ethinylestradiol in Italy did not significantly change after EMA recommendations.

Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.

Abrocitinib may effectively treat stubborn alopecia universalis.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.

Baricitinib was effective in treating both early and late onset alopecia areata.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Oral bicalutamide is safe and effective for female hair loss.